Cost Effectiveness of Pharmacotherapies in Early Parkinson's Disease

Author： Eggert Karla M.   Reese Jens P.   Oertel Wolfgang H.   Dodel Richard  

Publisher： Adis International

ISSN： 1172-7047

Source： CNS Drugs, Vol.22, Iss.10, 2008-01, pp. : 841-860

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pramipexole and Levodopa in Early Parkinson's Disease: Dynamic Changes in Cost Effectiveness

By Noyes Katia   Dick Andrew W.   Holloway Robert G.   The Parkinson Study Group  

PharmacoEconomics, Vol. 23, Iss. 12, 2005-01 ,pp. : 1257-1270

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Pramipexole in Parkinson's Disease in the US

By Hoerger T.J.  

PharmacoEconomics, Vol. 14, Iss. 5, 1998-11 ,pp. : 541-557

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson's Disease in the UK Setting: An Economic Markov Model Evaluation

By Haycox Alan  

Drugs & Aging, Vol. 26, Iss. 9, 2009-09 ,pp. : 791-801

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson's Disease in the UK Setting:: An Economic Markov Model Evaluation

By Kovacs Norbert   Janszky Jozsef   Nagy Ferenc  

Drugs & Aging, Vol. 28, Iss. 2, 2011-02 ,pp. : 161-162

Adis International

Access to resources Recommend Favorite

Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: A Methodological Review

By Dams Judith  

PharmacoEconomics, Vol. 29, Iss. 12, 2011-12 ,pp. : 1025-1049

Adis International

Access to resources Recommend Favorite